Connect for Well-being & Longevity

Phase II investigator-initiated clinical trial of RE-01 cell therapy for refractory ischemic (non-arteriosclerotic) lower extremity ulcers caused by Buerger's disease and collagen diseases initiated.

The key to azelaic acid lies in "how it's dissolved." A low-irritation serum formulation demonstrating acne-fighting efficacy comparable to a 20% cream has been established.

Rohto Pharmaceutical has published the "ROHTO Well-being Report - Integrated Report 2026".

Announcement Regarding the Acquisition of OP Biofactory as a Subsidiary

Supporting the establishment of the "General Incorporated Association for the Study of Ectopic Fat."

Regarding the status of the investigation into unauthorized access to our systems

Regarding the possibility of unauthorized access to our system

Announcement of the publication of "Rohto Health White Paper 2026"

Notice Regarding Voluntary Recall of Vietnamese-Made Eye Drops in the United States

Regarding support for the 2026 Kumamoto Earthquake

We are pleased to announce the recipients of the 20th Rohto Prize, a research fund specializing in "Japanese Association of Geriatric Dermatology Research Fund skin."

The recipients of the 17th Rohto Women's Health Science Research Award have been decided.

The winners of the 31st ROHTO AWARD research grants have been decided.

Recipients of the "Japanese Dermatological Association Dermatological Research Fund (Endowment by Rohto Pharmaceutical)" have been decided

We are pleased to announce the 19th recipient of Rohto Prize, a research fund specializing in Japanese Association of Geriatric Dermatology Research Fund skin.